|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008976,
umls-concept:C0012634,
umls-concept:C0021734,
umls-concept:C0025202,
umls-concept:C0030705,
umls-concept:C0079613,
umls-concept:C0079722,
umls-concept:C0205390,
umls-concept:C0443203,
umls-concept:C0443315,
umls-concept:C0473169,
umls-concept:C1257890,
umls-concept:C1522405
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
1999-7-8
|
|
pubmed:abstractText |
On the basis of our previous experience, we designed this study to determine the activity and toxicity of outpatient treatment with autologous tumor-infiltrating lymphocytes (TIL) together with intermediate-dose recombinant interleukin-2 (rIL-2) and low-dose recombinant interferon alfa-2a (rIFN-alpha2a), for patients with metastatic melanoma.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1068-9265
|
|
pubmed:author |
pubmed-author:CafieroFF,
pubmed-author:GipponiMM,
pubmed-author:LionettoRR,
pubmed-author:MelioliGG,
pubmed-author:PeressiniAA,
pubmed-author:PietraGG,
pubmed-author:PonteMM,
pubmed-author:QueiroloPP,
pubmed-author:RibizziII,
pubmed-author:SeminiEE,
pubmed-author:SertoliM RMR,
pubmed-author:VecchioSS
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
6
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
272-8
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:10340886-Adult,
pubmed-meshheading:10340886-Aged,
pubmed-meshheading:10340886-Drug Therapy, Combination,
pubmed-meshheading:10340886-Female,
pubmed-meshheading:10340886-Humans,
pubmed-meshheading:10340886-Immunotherapy, Adoptive,
pubmed-meshheading:10340886-Interferon-alpha,
pubmed-meshheading:10340886-Interleukin-2,
pubmed-meshheading:10340886-Lymphatic Metastasis,
pubmed-meshheading:10340886-Lymphocytes, Tumor-Infiltrating,
pubmed-meshheading:10340886-Male,
pubmed-meshheading:10340886-Melanoma,
pubmed-meshheading:10340886-Middle Aged,
pubmed-meshheading:10340886-Pilot Projects,
pubmed-meshheading:10340886-Recombinant Proteins,
pubmed-meshheading:10340886-Skin Neoplasms
|
|
pubmed:articleTitle |
Adoptive immunotherapy with tumor-infiltrating lymphocytes and subcutaneous recombinant interleukin-2 plus interferon alfa-2a for melanoma patients with nonresectable distant disease: a phase I/II pilot trial. Melanoma Istituto Scientifico Tumori Group.
|
|
pubmed:affiliation |
Department of Medical Oncology, University of Genoa, Italy.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase II,
Clinical Trial, Phase I
|
